Skip to content

Research on the Effects of Oliceridine on Perioperative Neurocognitive Function and Its Mechanisms

Research on the Effects of Oliceridine on Perioperative Neurocognitive Function and Its Mechanisms

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088248
Enrollment
Unknown
Registered
2024-08-14
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative neurocognitive disorders

Interventions

Group Oliceridine Group:The PCIA formula for the oliceridine group is oliceridine 30mg and ondansetron 16mg diluted to 150ml, with an initial dose of 7.5ml. The lockout time is 6 minutes, and the PCA
Group Morphine Group:The Morphine Group PCIA formula consists of 80 mg of morphine and 16 mg of ondansetron diluted to 150 ml, with an initial dose of 8 ml, a PCA dose of 2 ml, and a lockout time of 6

Sponsors

Jiangsu Province People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Family members and patients consented to participate in this study. (2) Patients scheduled for pancreatic surgery who agree to postoperative use of patient-controlled analgesia pump. (3) Age > 60 years old. (4) Patients without severe hearing or visual impairment and able to read.

Exclusion criteria

Exclusion criteria: (1) Patient or family refusal to participate in this study. (2) Severe diseases affecting cardiovascular, respiratory, hepatic, renal, or central nervous systems. (3) Life expectancy less than 12 months. (4) MMSE (Mini-Mental State Examination) score less than 23. (5) Currently using sedatives, antidepressants, or corticosteroids. (6) Alcohol or drug abuse. (7) Difficulty in follow-up or poor compliance.

Design outcomes

Primary

MeasureTime frame
incidence of postoperative delirium;Incidence of delayed neurocognitive recovery;Incidence of neurocognitive disorders;

Secondary

MeasureTime frame
Lung complications ;biochemical indicators;analgesic effect;

Countries

China

Contacts

Public ContactChun Yang

Jiangsu Province People's Hospital

2037419@qq.com+86 186 2781 6797

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026